RDNT
RadNet, Inc.
RDNT lost money over the past year, so it has no meaningful PE right now. Analysts expect earnings to recover, though they disagree widely on how much.
RDNT Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Healthy | |
| Stable |
RDNT's revenue and cash flow are currently healthy, and its balance sheet is stable, but its profitability is under pressure.
RDNT PE Valuation
RDNT has no meaningful PE right now: it lost money over the past year.
RDNT Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Strong growth | |
| Growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect earnings and revenue growth for RDNT, with profitability holding steady. However, they disagree widely on these estimates.
RDNT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.67 | — |
| Q3 2026 | -$0.28 | -$0.11 |
| Q2 2026 | -$0.26 | -$0.06 |
| Q1 2026 | -$0.17 | +$0.26 |
| Q4 2025 | -$0.25 | -725% |
| Q3 2025 | -$0.17 | -$0.17 |
| Q2 2025 | -$0.20 | -195% |
| Q1 2025 | -$0.43 | -216% |
| Q4 2024 | $0.04 | -20% |
RDNT is still losing money, but less than at its worst: $0.28 per share over the past year, against $0.43 at its worst in early 2025.
RDNT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $638.3M | +22% |
| Q2 2026 | $622.7M | +25% |
| Q1 2026 | $575.6M | +22% |
| Q4 2025 | $547.7M | +15% |
| Q3 2025 | $522.9M | +13% |
| Q2 2025 | $498.2M | +8.4% |
| Q1 2025 | $471.4M | +9.2% |
| Q4 2024 | $477.1M | +13% |
RDNT's revenue has grown year over year every quarter since late 2020: $638M last quarter, up 22% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 4.7% | -0.5 points |
| Q2 2026 | 6.3% | +0.1 points |
| Q1 2026 | -4.2% | +1 points |
| Q4 2025 | 5.1% | -0.1 points |
| Q3 2025 | 5.2% | -2.1 points |
| Q2 2025 | 6.2% | -1.4 points |
| Q1 2025 | -5.1% | -7.7 points |
| Q4 2024 | 5.1% | -0.7 points |
RDNT's operating margin was 4.7% last quarter, down 0.5 points from the same quarter a year ago.
RDNT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $35.1M | +$42.7M |
| Q2 2026 | $37.8M | -44% |
| Q1 2026 | $9M | +$16.4M |
| Q4 2025 | $33.1M | +$33.5M |
| Q3 2025 | -$7.6M | -147% |
| Q2 2025 | $67.4M | -2.8% |
| Q1 2025 | -$7.4M | +$33M |
| Q4 2024 | -$377K | -101% |
RDNT generated $115M in free cash flow over the past year, up 121% from the year before.
RDNT Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 2.3x | Moderate |
| Q2 2026 | 2.5x | Moderate |
| Q1 2026 | 2.8x | Moderate |
| Q4 2025 | 1.5x | Healthy |
| Q3 2025 | 1.4x | Healthy |
| Q2 2025 | 1.3x | Healthy |
| Q1 2025 | 1.4x | Healthy |
| Q4 2024 | 1.1x | Healthy |
RDNT's net debt is about 2.3 years of its operating earnings (EBITDA), up from 1.4 years a year ago.
RDNT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 60.3 | Neutral |
| Stochastic | 65.1 | Neutral |
RDNT's weekly RSI is 60 (neutral) and its Stochastic is 65 (neutral).
RDNT PE vs Healthcare Sector
| Metric | RDNT | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
RDNT has no meaningful PE right now: it lost money over the past year.
RDNT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $72.0 | 5.6% above |
| 20 week MA | $71.2 | 6.8% above |
| 50 week MA | $66.8 | 14% above |
| 100 week MA | $65.1 | 17% above |
| 200 week MA | $54.2 | 40% above |
RDNT is in an uptrend: it's above all five of its weekly moving averages, and 40% above its 200-week average.
RDNT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $19.9 | $18.7 | -5.8% |
| 2021 | $18.7 | $30.4 | +62% |
| 2022 | $30.4 | $18.9 | -38% |
| 2023 | $18.9 | $34.8 | +84% |
| 2024 | $34.8 | $71.3 | +105% |
| 2025 | $71.3 | $73.2 | +2.6% |
| 2026 YTD | $73.2 | $76.0 | +4% |
RDNT has finished higher in four of the last six years, three of them by more than 50%. It's up 4% so far in 2026.